Citigroup Maintains Buy on Surgery Partners, Lowers Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Jason Cassorla maintains a Buy rating on Surgery Partners (NASDAQ:SGRY) but lowers the price target from $42 to $38.

May 08, 2024 | 7:11 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Surgery Partners but lowers the price target from $42 to $38.
While the reduction in price target could suggest a tempered outlook on the stock's short-term price potential, the maintenance of a Buy rating indicates a continued positive view on the company's fundamentals. This mixed signal could lead to a neutral short-term impact on the stock price as investors weigh the lowered price target against the analyst's ongoing endorsement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100